Parexel has partnered with the Japanese Foundation for Cancer Research (JFCR) to “accelerate access to oncology clinical trials in Japan.”
The partnership – financial terms of which have not been disclosed – will see sites run by the JFCR become the contract research organization’s (CRO’s) preferred location for cancer-related drug studies in the country.
In addition, Parexel will work with JFCR experts to help sponsors develop trial protocols that align with Japan's standard of care and approval processes — with the aim being to speed patient recruitment and study start-up.
In a press statement Shigehiro Miki, the CRO’s corporate VP and general manager in Japan, said: “We look forward to JFCR joining Parexel’s Site Alliance Network and working together to eliminate barriers and increase the access of potentially life-changing treatments to Japanese patients.”
JFCR is Japan’s largest medical organization dedicated to cancer care. The organization is known for its cross-functional, holistic cancer center, state-of-the-art research facilities and extensive number of patients under their care.
Parexel’s site network consists of more the 480 locations that employ more than 21,000 researchers worldwide.
Asia pacific focus
The agreement with JFCR is an extension of the CRO’s strategy of driving clinical innovation in key therapeutic areas, such as oncology, in the Asia/Pacific region.
Parexel maintains relationships with other alliance sites in the region, including Osaka International Cancer Institute and Kyoto University Hospital.
The latter collaboration – set up in 2021 – has focused on finding opportunities for clinical research and producing efficient and productive ways of supporting studies through the hospital’s Ki-connect program. At the time Parexel told us the partnership would make extensive use of decentralized studies, with a particular focus on regenerative medicines.
The CRO has similar partnerships in China with the Beijing Illness Challenge Foundation and the Cancer Hospital Chinese Academy of Medical Sciences.